00:00 / 00:00
Niemann-Pick disease types A and B (NORD)
0 / 12 complete
0 / 2 complete
Niemann-Pick disease p. 86
Niemann-Pick disease type A and type B, or NPD-A and NPD-B, which are subtypes of acid sphingomyelinase or ASM deficiency, are rare, genetically inherited conditions characterized by the inability to break down a fat called sphingomyelin due to a deficiency of the enzyme, acid sphingomyelinase.
There’s also Niemann-Pick disease type C, which is known to be caused by mutations in the genes NPC1 and NPC2, and is therefore considered to be distinct from types A and B.
Sphingomyelin is a fat that's included in the membrane of many different cells.
They contain organelles called lysosomes that are said to function as recycling centers because they break down large, potentially harmful substances to be reused by the body.
They break down sphingomyelin by using an enzyme called acid sphingomyelinase, which is a product of the sphingomyelin phosphodiesterase 1, or SMPD1 gene.
In Niemann-Pick disease types A and B, there’s a mutation in the SMPD1 gene that causes a defect in the production of sphingomyelinase, leading to an inability to break down sphingomyelin.
In NPD-A there’s almost a complete absence of sphingomyelinase activity, while NPD-B has some residual sphingomyelinase activity remaining.
The macrophages develop a characteristic lipid-laden appearance under microscopes and are called “foam cells.”
Sphingomyelin can also build up in other cell types in the body, reflecting impaired intracellular recycling of membranes and damaged organelles in lysosomes due to sphingomyelinase deficiency.
Signs and symptoms of NPD-A present early in life, and are usually life-threatening.
Niemann-Pick disease (NPD) type A and type B, are rare inherited conditions characterized by the inability to break down sphingomyelin, due to a deficiency of the enzyme acid sphingomyelinase. Niemann-Pick disease type A and type B result from SMPD1 gene mutation, which normally encodes to sphingomyelinase enzyme.
NPD-A symptoms present early in life and may include hepatosplenomegaly, jaundice, feeding difficulties, and progressive loss of reflexes and muscle tone. It is also often associated with a cherry red spot � in the eye, which affects the macula and impairs central vision. Usually, NPD-A becomes fatal by the age of 3 years old.
On the other hand, NPD-B represents a less severe condition that typically does not include neurologic involvement, and can develop at any time in life. Common NPD-B symptoms include progressive splenomegaly, which causes low serum platelet and white blood cell levels, high cholesterol, and declining lung function. There is no cure for NPA and NPB, and treatment is supportive and focuses on managing symptoms.
Copyright © 2023 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.